Femme Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
to compare the investigator assessed progression-free survival (PFS) following treatment with single agent neratinib versus lapatinib plus capecitabine in subjects with erbB2 positive locally advanced or metastatic breast cancer.
Critère d'inclusion
- Locally advanced or metastatic breast cancer